Priscilla Brastianos, MD

Priscilla Brastianos, MD, Dana-Farber Cancer Institute

Fellow in Medical Oncology at the Dana-Farber Cancer Institute.

Medical Education:

Johns Hopkins University School of Medicine

Residency:

Internal Medicine, Johns Hopkins School of Medicine, Baltimore

Fellowship:

Medical Oncology, Dana-Farber Cancer Institute and Massachusetts General Hospital

Mentors:

Dr. William Hahn, Dr. Rameen Beroukhim, Dr. Tracy Batchelor, Dr. Jose Baselga

Clinical Interests:

Metastasis to the Central Nervous System

Dr. Brastianos received her BSc in biochemistry and chemistry from the University of British Columbia, where she graduated as her class valedictorian. She received multiple awards, including the Wesbrook Scholar award, the Science Scholar Award, the Canadian Society for Chemistry Prize, the Violet and Blythe Eagles Undergraduate Prize in Biochemistry and the Logan and Harold B. Nellie Boyes Memorial Scholarship. She completed her medical school training at Johns Hopkins School of Medicine, and her internal medicine residency training at Johns Hopkins Hospital. While at Johns Hopkins, she performed research studying animal models of metastasis to the central nervous system. She received the Johns Hopkins Medical Student Award for Excellence in Research, the national Leah J. Dickstein, MD, award for leadership and scholarship, and the Bradley Benton Davis Research Award from the American Brain Tumor Association. Following her training at Johns Hopkins, she pursued her fellowship training at the Dana-Farber Cancer Institute.

Dr. Brastianos’ research focuses on understanding the molecular mechanisms of metastasis to the central nervous system. As a postdoctoral fellow in Dr. William Hahn’s laboratory, she is working on the genomic characterization of brain metastases. She works very closely with Dr. Rameen Beroukhim, and others at the Broad Institute, to use cutting-edge sequencing technology to understand the genetic alterations in metastatic disease. Her hope is that they will identify new therapeutic targets to treat this devastating complication of cancer.